CAS launches new AI-enhanced CAS SciFinder platform to accelerate scientific discovery
The updated CAS SciFinder integrates domain-specific AI and curated scientific content to improve research efficiency,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Latest Updates
Laborate Pharmaceuticals secures EU-GMP certification for oral solid dosage facility
The certification enables Laborate Pharmaceuticals to access European Union and other regulated markets, with plans to file 20…
Gerresheimer to separate moulded glass and intends to initiate a subsequent sales process
Further step in Gerresheimer's strategic transformation into a system and solution provider purely for the pharma and biotech…
Nanoscope Therapeutics’ MCO-010 holds potential to become new treatment option for retinitis:…
GlobalData outlines how Nanoscope’s BLA submission for MCO-010 underscores a possible shift in the retinitis pigmentosa treatment…
Zenara Pharma receives US FDA approval for generic Sertraline Hydrochloride Capsules
FDA grants Zenara 180-day marketing exclusivity for first generic version of Almatica Pharma’s Sertraline Hydrochloride Capsules
Concept Medical announces first patient enrolment in MAGICAL-SV IDE trial
The trial evaluates the MagicTouch Sirolimus-Coated Balloon (SCB) against drug-eluting stents in the treatment of small coronary…
Eli Lilly launches new technology and innovation site in Hyderabad
The Hyderabad site will serve as a strategic digital operations centre for Eli Lilly, focusing on AI, cloud, and automation, with…
India’s pharma funding reaches $294 million in July 2025
Pharma funding snapshot highlights late-stage dominance and surge in capital flow, with Meril’s $200M round leading July’s…
US-EU trade deal puts pharma industry at substantial fiscal risk: GlobalData
The imposition of tariffs threatens to elevate costs, creating uncertainty in launch planning, particularly for late-stage assets…
Lilly’s Mounjaro (tirzepatide) demonstrated cardiovascular protection in a head-to-head trial
Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8 per cent lower rate of MACE-3 events, while…
Touchlight introduces mbDNA: A circular single-stranded DNA (ssDNA) platform enabling superior gene…
mbDNA’s design supports 1-20kb gene insertions and aims to offer more knock-in efficiency across diverse cell types
Pharmexcil drives global pharma trade through premier healthcare export summit
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets…
Walking the talk on ESG, workplace safety
Proactively investing in employee and workplace safety is not just good for employees, but makes smart business sense
VedTechBio partners with AlphaMeld in multi-therapy collaboration
VedTechBio Research also announced enhancements to its RxAgentAI platform, a multi-agentic intelligence system augmented by deep,…
Ayush sector can define India’s leadership in integrative medicine, says Ayush Minister
Ayush Stakeholders Unite to Chart Vision for ‘Viksit Bharat’ at FICCI Consultative Meeting 2025
Symbiosis completes 1,000th batch of injectable drug product
Symbiosis played a pivotal role in the clinical development of the Oxford University/AstraZeneca COVID-19 vaccine
Hans-Norbert Topp to take over management of the Gerresheimer moulded glass business unit
With the acquisition of Bormioli Pharma, Gerresheimer has expanded its moulded glass production network by two additional plants…
AI adoption surges in life sciences manufacturing as talent, risk, and quality pressures intensify
Global survey reveals how manufacturers are adopting advanced technologies to stay competitive and meet rising patient demands
Industry reacts to Trump’s 25 per cent tariff penalty, highlighting its implications on pharma
While the immediate consequences of these tariffs will likely result in increased costs for essential drugs, the long-term impact…
Early Alzheimer’s patients continue to benefit from 4 yrs of LEQEMBI(R) (lecanemab-irmb)…
Data showed LEQEMBI slowed clinical decline by 1.75 points on CDR-SB at four years compared to the natural history of Alzheimer’s…